Frequency and characteristics of chemotherapy-associated thrombotic microangiopathy: Analysis from a large pharmacovigilance database,American Journal of Hematology

当前位置： X-MOL 学术 › Am. J. Hematol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Frequency and characteristics of chemotherapy-associated thrombotic microangiopathy: Analysis from a large pharmacovigilance database
American Journal of Hematology ( IF 10.1 ) Pub Date : 2023-09-23 , DOI: 10.1002/ajh.27101
Nattawat Klomjit ₁ , Richard Evans ₂ , Thomas K Le ₃ , Sophia L Wells ₄ , Jessica Ortega ₄ , Olivia Green-Lingren ₄ , Marshall Mazepa ₅ , Meghan E Sise ₆ , Kenar D Jhaveri ₇ , Shruti Gupta _{4,

8}

Affiliation

We used the information component (IC), a disproportionate Bayesian analysis comparing the number of observed versus expected adverse drug reactions, to determine the potential association between anti-neoplastic agents and thrombotic microangiopathy (TMA). The IC₀₂₅ indicates the lower end of 95% of IC, in which a value >0 suggests a disproportionality signal between the drug of interest and the adverse drug reaction. Carfilzomib had the highest IC₀₂₅ for TMA among all studied chemotherapies followed by gemcitabine, mitomycin, bevacizumab, and bortezomib.

中文翻译：

化疗相关血栓性微血管病的频率和特征：大型药物警戒数据库的分析

我们使用信息成分（IC），一种不成比例的贝叶斯分析，比较观察到的药物不良反应与预期的药物不良反应的数量，以确定抗肿瘤药物与血栓性微血管病（TMA）之间的潜在关联。 IC ₀₂₅表示 IC 95% 的下限，其中值 >0 表明感兴趣的药物与药物不良反应之间存在不成比例的信号。在所有研究的化疗中，卡非佐米对 TMA 的 IC ₀₂₅最高，其次是吉西他滨、丝裂霉素、贝伐单抗和硼替佐米。

更新日期：2023-09-23

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南